Press Release: Novartis Kisqali(R) significantly -3-

21. European Society for Medical Oncology -- Magnitude of Clinical Benefit

Scale Scorecard. Published April 20, 2020. Updated August 21, 2020.

Accessed May 31, 2023.

https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard

-158-1.

22. European Society for Medical Oncology -- Magnitude of Clinical Benefit

Scale Scorecard. Published March 29, 2022. Accessed May 31, 2023.

https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard

-9-1.

23. Ribociclib vs. palbociclib in patients with advanced breast cancer within

the HER2-enriched intrinsic subtype (HARMONIA). Identifier NCT05207709.

Revised April 4, 2022. Accessed May 31,

2023. https://clinicaltrials.gov/ct2/show/NCT05207709

24. Novartis and Vestre Viken Hospital Trust (2022, April 1 -- 2024, December

1). Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With

Ribociclib and Letrozole (NEOLETRIB). Identifier NCT05163106. Accessed

May 31, 2023. https://clinicaltrials.gov/ct2/show/NCT05163106

**Ibrance(R) is a registered trademark of Pfizer, Inc.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Central North America

Richard Jarvis +41 79 584 2326 Julie Masow +1 862 579 8456

Anja von Treskow +41 79 392 9697 Michael Meo +1 862 274 5414

Anna Schäfers +41 79 801 7267 Mary Carmichael +1 862 200 8344

Marlena Abdinoor +1 617 335 9525

Switzerland

Satoshi Sugimoto +41 79 619 2035

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440

Nicole Zinsli-Somm +41 61 324 3809 Parag Mahanti +1 973 876 4912

Isabella Zinck +41 61 324 7188

(END) Dow Jones Newswires

June 02, 2023 08:00 ET (12:00 GMT)